Topical Infliximab in Autoimmune Eyes With Keratoprosthesis
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 30 Oct 2018
Price : $35 *
At a glance
- Drugs Infliximab (Primary)
- Indications Pemphigoid; Stevens-Johnson syndrome; Toxic epidermal necrolysis
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 05 Apr 2017 Status changed from recruiting to withdrawn prior to enrolment as No patients met eligibility criteria.
- 03 Apr 2017 Planned End Date changed from 1 Mar 2017 to 3 Apr 2017.